Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Total Liabilities: 2016-2025

Historic Total Liabilities for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to $211.2 million.

  • Rhythm Pharmaceuticals' Total Liabilities rose 0.15% to $211.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $211.2 million, marking a year-over-year increase of 0.15%. This contributed to the annual value of $227.7 million for FY2024, which is 39.72% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Total Liabilities is $211.2 million, which was down 11.69% from $239.2 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Total Liabilities' 5-year high stood at $239.2 million during Q2 2025, with a 5-year trough of $33.6 million in Q3 2021.
  • Its 3-year average for Total Liabilities is $189.6 million, with a median of $202.4 million in 2024.
  • Data for Rhythm Pharmaceuticals' Total Liabilities shows a peak YoY spiked of 223.06% (in 2022) over the last 5 years.
  • Over the past 5 years, Rhythm Pharmaceuticals' Total Liabilities (Quarterly) stood at $45.4 million in 2021, then skyrocketed by 160.55% to $118.2 million in 2022, then surged by 37.87% to $163.0 million in 2023, then surged by 39.72% to $227.7 million in 2024, then increased by 0.15% to $211.2 million in 2025.
  • Its last three reported values are $211.2 million in Q3 2025, $239.2 million for Q2 2025, and $223.6 million during Q1 2025.